ASX:SOM SomnoMed (SOM) Stock Price, News & Analysis → my top trade on these 9 tickers (From DTI) (Ad) Free SOM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume95,124 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield2.25%Price TargetN/A Stock AnalysisStock Analysis Get SomnoMed alerts: Email Address Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About SomnoMedSomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral appliances for the treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. Its flagship product SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs are cleaning tablets, developed to clean oral appliances safely and effectively. In addition, it also provides sleep test at home under the Sunrise brand name. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.Read More Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here SOM Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive SOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SomnoMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:SOM CUSIPN/A CIKN/A Websomnomed.com Phone61 2 9467 0400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-0.09Net Income$-10,510,000.00 Net Margins-11.94% Pretax MarginN/A Return on Equity-38.28% Return on Assets-6.34% Debt Debt-to-Equity Ratio62.00 Current Ratio1.73 Quick Ratio1.05 Sales & Book Value Annual Sales$88.77 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.61 Book ValueA$0.28 per share Price / BookN/AMiscellaneous Outstanding Shares108,590,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.02 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Neil Verdal-Austin B.Com.C.A., Global CEO, MD & DirectorMr. Mark HardingVice President of Global MarketingMr. Matthew ConlonExecutive VP of Sales & Marketing - North AmericaMr. Marco Van KleefVice President of Marketing & Sales - EuropeMr. Darren Collins ACA (Age 55)B Comm, Chief Financial Officer Mr. Terence A. Flitcroft B.Com. (Age 65)B.Comm., C.A., SF FIN, Company Secretary Comp: $27.25kMr. Christopher BedfordVice President of Global Production and Product DevelopmentMore ExecutivesKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersNeil Verdal-AustinSold 160,000 sharesTotal: $64,000.00 ($0.40/share)Amrita BlicksteadSold 23,856 sharesTotal: $14,313.60 ($0.60/share)Hilton BrettSold 39,854 sharesTotal: $23,912.40 ($0.60/share)Hamish CorlettSold 5,840,618 sharesTotal: $3.50 M ($0.60/share) This page (ASX:SOM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & CompanyUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SomnoMed Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.